中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

休市中 09-11 16:08:55

5.250

-0.230

-4.20%

最高5.480	最低5.235	成交量7,216万
今开5.480	昨收5.480	日振幅4.47%
总市值980.86亿	流通市值980.86亿	总股本186.83亿
成交额3.81亿	换手率0.39%	流通股本186.83亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":5.25,"timestamp":1789114135002,"preClose":5.48,"halted":0,"volume":72163612,"delay":0,"changeRate":-0.0419708029197081,"floatShares":18683000000,"shares":18683000000,"eps":0.1518054916852311,"marketStatus":"休市中","change":-0.23,"latestTime":"09-11 16:08:55","open":5.48,"high":5.48,"low":5.235,"amount":381463776,"amplitude":0.044708,"askPrice":5.25,"askSize":1242000,"bidPrice":5.245,"bidSize":1112000,"shortable":3,"etf":0,"ttmEps":0.15468256708292805,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":7,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":5.48,"dividendRate":0.022876,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":0.8172276667756744,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.0854,"impliedVolPercentile":0.0204},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"2666540438","title":"中国生物制药（01177）拟收购主要股东旗下公司股权以收购正大天晴5%股权 涉资44.8亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666540438","media":"金吾财讯","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666540438?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:11","pubTimestamp":1789117861,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国生物制药（01177）发布公告，公司拟通过向主要股东收购Sino Harmony Ventures Limited雍华创投有限公司的股权，以收购正大天晴5%股权，代价为44.8亿元人民币。正大天晴为公司的附属公司，于交割时，公司间接持有正大天晴的股权将由60%增加至65%。以2026年6月底正大天晴LTM经调整归母净利润计，可增厚集团经调整归母净利润约7.4%（即约3.5亿人民币）。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/YThlNWYyZDkwZDI4NjgyMzY1OTg4MDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YThlNWYyZDkwZDI4NjgyMzY1OTg4MDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991444","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","01177","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","HK0000165453.HKD","BK1521","BK1515","IE00BZ08YS42.EUR","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136876179","title":"中国生物制药拟44.8亿元收购正大天晴5%股权 持股将增至65%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136876179","media":"公告速递","labels":["shareholding","merge","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136876179?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:41","pubTimestamp":1789116064,"startTime":"0","endTime":"0","summary":"2026年9月11日，中国生物制药公告称，旗下全资子公司Chia Tai Pharmaceutical  Company Limited已与公司执行董事兼主要股东谢承润先生签订股份买卖协议，拟以44.8亿元人民币现金收购雍华创投有限公司100%股权。交易完成后，中国生物制药通过间接持股的方式在正大天晴的权益比例将由60%增至65%。中国生物制药预计，本次增持将使集团经调整归母净利润增加约3.5亿元，占比约7.4%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666547461","title":"中国生物制药(01177.HK)拟44.8亿元向谢承润收购正大天晴5%股权 完成后间接持股增至65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666547461","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666547461?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:37","pubTimestamp":1789115835,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","IE00BZ08YS42.EUR","01177","IE00BZ08YR35.GBP","BK1521","BK1589","HK0000165453.HKD","BK1191","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164324018","title":"中国生物制药拟以44.8亿元人民币收购正大天晴5%股权，对应市盈率19倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1164324018","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164324018?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:31","pubTimestamp":1789115473,"startTime":"0","endTime":"0","summary":"中国生物制药宣布，其附属公司SBP集团将斥资44.8亿元人民币，用以收购正大天晴5%的股权权益。此项交易的定价依据为过去十二个月市盈率约19倍，反映出公司对正大天晴未来盈利潜力的充足信心。据悉，此次股权收购将进一步巩固中国生物制药在正大天晴中的股东地位，并有望深化双方在医药研发、生产及市场拓展等方面的战略协同效应。交易完成后，中国生物制药在正大天晴的持股比例将有所提升，预计将对集团的合并报表利润产生积极影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","01177","BK1515","BK1191","BK1521","HK0000165453.HKD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147757557","title":"异动解读｜中国生物制药盘中下跌3.19%，报5.295港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1147757557","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147757557?lang=zh_cn&edition=full","pubTime":"2026-09-11 09:49","pubTimestamp":1789091393,"startTime":"0","endTime":"0","summary":"9月11日，中国生物制药盘中下跌3.19%，报5.295港元/股，成交额3635.23万港元。中国生物制药所在的制药行业中，个股涨跌不一，其中石药集团跌2.28%，翰森制药跌2.88%，长风药业涨10.42%，康哲药业涨0.55%，恒瑞医药跌1.59%。中国生物制药是一家主要从事制药业务的投资控股公司，业务涵盖中药现代制剂及西药产品的生产、销售与分销，以及长期投资和相关医疗及医院业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666128556","title":"【券商聚焦】中信证券：中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666128556","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666128556?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:59","pubTimestamp":1789001960,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年以来，中国创新药国内市场快速放量，从中报来看头部创新药企业在新产品驱动下，创新药收入快速增长，biopharma陆续进入盈利拐点；出海创新药开始进入三期/注册研究兑现阶段；近期多个国际学术大会将至，众多创新药管线进入密集的数据催化期。该机构认为中国创新药进入全球价值兑现阶段，建议关注：①头部国际化创新药企业有望迎来产品全球价值兑现期；②头部创新药企业产品放量进入新的成长阶段；③具有全球潜力的管线资产国际化有望加速兑现。综上，我们维持创新药行业“强于大市”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991210","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1880383366.USD","LU1255011170.USD","06030","IE00B543WZ88.USD","01093","LU0561508036.HKD","LU0979878070.USD","LU1794554557.SGD","LU2580892862.HKD","09926","LU0417516738.SGD","LU1961090484.USD","600030","BK0028","01801","LU1226287875.USD","LU0405327494.USD","LU1997245177.USD","LU0819121731.USD","06160","09688","BK1141","LU2148510915.USD","LU2039709279.SGD","02616","BK1161","LU1655091616.SGD","KCE","LU0348783233.USD","09995","LU1720050803.USD","02269","01877","KURE","LU1820825898.SGD","SG9999004220.SGD","LU0516422952.EUR","01177","06185","LU0463099449.HKD","02142","LU0572944931.SGD","LU1813983027.USD","LU0181495838.USD","LU1064130708.USD","LU1969619763.USD","LU0348825331.USD","LU1226287792.SGD","LU1580142542.USD","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666831355","title":"瑞银：中国制药股上半年业绩好坏参半 首选先声药业(02096)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666831355","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666831355?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:43","pubTimestamp":1788939780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，中国制药股上半年业绩好坏参半，在九家评级的制药公司中，有五家业绩好过市场预期，分别为翰森制药、先声药业、中国生物制药、石药集团及科伦药业，联邦制药表现大致符合预期，而三生制药及华东医药表现则逊预期，全数给予“买入”评级。瑞银列先声药业行业首选股，指出先声药业是唯一上调2026年指引的公司，经调整纯利增长目标由30%上调至45%，收入增长维持30%，给予目标价16.6港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","BK1593","BK1583","03933","03692","IE00B3M56506.USD","BK1521","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","01177","02096","01530","BK1515","BK1191","BK1161","BK1574","BK1589","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100428950","title":"异动解读｜中国生物制药盘中下跌3.08%，报5.665港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1100428950","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100428950?lang=zh_cn&edition=full","pubTime":"2026-09-09 13:35","pubTimestamp":1788932138,"startTime":"0","endTime":"0","summary":"9月9日，中国生物制药盘中下跌3.08%，报5.665港元/股，成交额3.14亿港元。中国生物制药所在的制药行业中，个股普遍承压，其中石药集团跌7.59%，翰森制药跌0.67%，和黄医药跌1.27%，凯莱英持平，复星医药涨0.46%。中国生物制药是一家主要从事制药业务的投资控股公司，业务涵盖中药现代制剂及西药产品的生产、销售与分销，以及长期投资和相关医疗及医院业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329142","title":"中国生物制药(01177)：TQH5528“口服STAT6降解剂”于ERS 2026公布临床前研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329142","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665329142?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:52","pubTimestamp":1788861125,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，集团附属公司正大天晴药业集团股份有限公司(“正大天晴”)自主研发的TQH5528“口服STAT6降解剂”已于欧洲呼吸学会2026年会(ERS 2026)上，以口头报告(Oral)形式公布临床前研究数据，并同步展示电子壁报(e-poster)。TQH5528是正大天晴基于全球自主知识产权的口服蛋白降解剂技术平台(OAPD®)开发的一款口服 STAT6降解剂。TQH5528靶向IL-4/IL-13/STAT6信号轴，依靠蛋白降解机制发挥药效，有潜力成为替代注射生物制剂、给药更便捷的新一代治疗药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药(01177)：TQH5528“口服STAT6降解剂”于ERS 2026公布临床前研究数据","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","HK0000165453.HKD","IE00BZ08YS42.EUR","01177","BK1521","IE00BZ08YT58.USD","BK1589","BK1191","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185136892","title":"中国生物制药（01177）公布TQH5528口服STAT6降解剂在ERS 2026发布临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1185136892","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185136892?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:51","pubTimestamp":1788861118,"startTime":"0","endTime":"0","summary":"2026年9月8日，中国生物制药（01177）发布自愿公告称，其附属公司正大天晴药业集团股份有限公司自主研发的TQH5528「口服STAT6降解剂」已在欧洲呼吸学会2026年会（ERS 2026）上以口头报告形式公布临床前研究数据，并同步展示电子壁报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665347968","title":"中国生物制药（01177）盘中拉升6.86% 机构指创新管线已进入密集兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665347968","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665347968?lang=zh_cn&edition=full","pubTime":"2026-09-08 14:14","pubTimestamp":1788848069,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国生物制药（01177）午后持续拉升，截至发稿，最新报5.85港元，涨幅6.86%，成交额4.23亿港元。消息面上，国盛证券研究指，公司深度聚焦抗肿瘤、呼吸、肝病及代谢等重大疾病领域，创新管线已进入密集兑现期，有望推动公司加速发展。预计公司2026-2028年营业收入分别为351.41/390.33/437.12亿元，同比增速分别为10.39%/11.08%/11.99%。该机构表示，看好公司进入加速发展阶段，通过可比公司估值法，给予公司2027年27倍PE，对应目标价8.20元港币，首次覆盖，给予“买入”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991016","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","IE00BZ08YR35.GBP","HK0000165453.HKD","BK1515","01177","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1191","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191280259","title":"异动解读｜中国生物制药盘中上涨3.02%，TQC3721吸入粉雾剂I期临床数据公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1191280259","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191280259?lang=zh_cn&edition=full","pubTime":"2026-09-08 11:03","pubTimestamp":1788836584,"startTime":"0","endTime":"0","summary":"9月8日，中国生物制药盘中上涨3.02%，报5.635港元，成交额1.29亿港元。消息面上，公司附属正大天晴药业自主研发的TQC3721吸入粉雾剂于欧洲呼吸学会年会上公布两项I期临床研究数据，各组不良事件发生率相似，安全性数据积极。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药上涨，TQC3721临床数据积极","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183255961","title":"中国生物制药（01177）披露TQC3721吸入粉雾剂I期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1183255961","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183255961?lang=zh_cn&edition=full","pubTime":"2026-09-07 18:42","pubTimestamp":1788777731,"startTime":"0","endTime":"0","summary":"2026年9月7日，中国生物制药有限公司公告称，其附属公司正大天晴药业集团股份有限公司自主研发的TQC3721吸入粉雾剂在欧洲呼吸学会2026年会上公布两项I期临床研究数据。各组不良事件发生率相似。公告称，TQC3721通过支气管扩张和抗炎双重机制发挥作用。针对COPD，TQC3721雾化吸入混悬液已在IIb期研究中取得积极结果，当前在中国开展III期临床试验，并被国家药监局药品审评中心列入突破性治疗药物名单；干粉吸入粉雾剂的II期临床试验亦取得积极顶线数据。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665131659","title":"中国生物制药(01177.HK)：TQC3721吸入粉雾剂(PDE3/4抑制剂)于ERS 2026公布I期临床研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2665131659","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665131659?lang=zh_cn&edition=full","pubTime":"2026-09-07 18:39","pubTimestamp":1788777571,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1521","BK1589","IE00BZ08YT58.USD","BK1515","HK0000165453.HKD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664815523","title":"【券商聚焦】国盛证券首予中国生物制药（01177）“买入”评级 指BD战略持续深化","url":"https://stock-news.laohu8.com/highlight/detail?id=2664815523","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664815523?lang=zh_cn&edition=full","pubTime":"2026-09-04 13:53","pubTimestamp":1788501184,"startTime":"0","endTime":"0","summary":"BD战略持续深化。肿瘤领域，公司聚焦胃癌、肺癌、乳腺癌及肿瘤免疫方向。我们看好公司进入加速发展阶段，通过可比公司估值法，给予公司2027年27倍PE，对应目标价8.20元港币，首次覆盖，给予“买入”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990703","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","002670","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238859","title":"【券商聚焦】交银国际：医药行业收入稳健增长 多重利好推动盈利表现显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238859","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238859?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:00","pubTimestamp":1788483634,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，1H26港股/A股医药行业整体收入增长4.7%/3.2%。创新药产业链增速领跑行业，服务板块复苏：1）港股/A股CXO收入整体增长29.2%/25.3%，（扣非）净利润增长23.4%/67.6%，在各子板块中增速最快，行业整体景气度和订单需求处于高位。2）核心成药板块收入增长17.8%/3.4%、利润增长62.7%/35.0%。其中生物药增速远超化药，在板块收入中的占比也进一步提升。3）医院、器械、诊断、疫苗等板块业绩有复苏趋势。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759","LU1880383366.USD","01951","09966","LU2543165471.USD","SG9999004220.SGD","06160","03329","BK1161","LU0348783233.USD","09926","09996","01801","01952","BK1589","KCE","06996","IE00B5MMRT66.SGD","HK0000320264.USD","LU0327786744.USD","06078","01177","01276","LU0856984785.SGD","LU0039217434.USD","06821","LU1152091168.USD","LU1251922891.USD","IE00B0JY6N72.USD","06990","03692","01530","LU1242518857.USD","KURE","02273","LU0307460666.USD","00013","BK1209","BK1515","LU0315179316.USD","IE00B543WZ88.USD","01548","02096","02162","LU0588546209.SGD","02268","01093","02269","02596","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151812720","title":"中国生物制药旗下GPC3靶向ADC获FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1151812720","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151812720?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:42","pubTimestamp":1788439339,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司9月3日公告称，其附属公司正大天晴药业集团股份有限公司自主研发的国家1类新药TQB6426「GPC3抗体药物偶联物」已获得美国食品药品监督管理局新药临床试验批准，拟用于治疗晚期恶性肿瘤。目前全球尚无靶向GPC3的ADC药物获批上市，相关候选产品仍处于临床前及早期临床阶段。本公告由中国生物制药有限公司董事会主席谢其润于2026年9月3日签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238088","title":"中国生物制药早盘涨超4% TQB6426获FDA批准开展临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238088","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238088?lang=zh_cn&edition=full","pubTime":"2026-09-03 10:28","pubTimestamp":1788402480,"startTime":"0","endTime":"0","summary":"模拟交易客户端中国生物制药早盘涨近5%。截至发稿，股价上涨4.47%，现报5.50港元，成交额1.54亿港元。中国生物制药旗下正大天晴自主研发的创新型GPC3抗体药物偶联物TQB6426，于近日获得美国食品药品监督管理局临床试验默认许可，拟用于晚期恶性肿瘤治疗。至此，TQB6426拿下中美两大核心医药市场临床准入资质，成为公司创新药全球化开发的重要里程碑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-03/doc-iniqpeka1141170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","BK1589","BK1515","BK4585","IE00BZ08YR35.GBP","BK1191","BK4588","IE00BZ08YT58.USD","BK1521","IE00BZ08YS42.EUR","01177","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664459828","title":"港股异动 | 中国生物制药(01177.HK)早盘涨近5% TQB6426获FDA批准开展临床 拟用于晚期恶性肿瘤治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2664459828","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664459828?lang=zh_cn&edition=full","pubTime":"2026-09-03 09:59","pubTimestamp":1788400759,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","IE00BZ08YT58.USD","BK1191","IE00BZ08YR35.GBP","BK1589","HK0000165453.HKD","BK1521","IE00BZ08YS42.EUR","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111443139","title":"异动解读｜中国生物制药盘中上涨3.33%，核心ADC新药TQB2102三期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1111443139","media":"行情直击","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111443139?lang=zh_cn&edition=full","pubTime":"2026-09-03 09:41","pubTimestamp":1788399706,"startTime":"0","endTime":"0","summary":"9月3日，中国生物制药盘中上涨3.33%，报5.44港元/股，成交额3464.22万港元。消息面上，公司旗下正大天晴自主研发的HER2双表位双抗ADC新药TQB2102治疗HER2低表达复发/转移性乳腺癌的Ⅲ期临床研究完成期中分析，经独立数据监查委员会判定，达到预设的主要终点和关键次要终点。这是全球首个HER2双表位双抗ADC在HER2低表达乳腺癌领域取得成功的Ⅲ期临床研究，公司已获CDE书面同意，将于近期递交上市申请。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药上涨，核心ADC新药临床达主要终点","news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":-0.0515},{"period":"1month","weight":0.0798},{"period":"3month","weight":0.1445},{"period":"6month","weight":-0.0959},{"period":"1year","weight":-0.3626},{"period":"ytd","weight":-0.1296}],"compareEarnings":[{"period":"1week","weight":-0.033},{"period":"1month","weight":-0.0249},{"period":"3month","weight":0.0035},{"period":"6month","weight":-0.0259},{"period":"1year","weight":-0.0491},{"period":"ytd","weight":-0.0322}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.006945},{"month":2,"riseRate":0.652174,"avgChangeRate":0.056473},{"month":3,"riseRate":0.565217,"avgChangeRate":0.04606},{"month":4,"riseRate":0.478261,"avgChangeRate":0.020913},{"month":5,"riseRate":0.695652,"avgChangeRate":0.038341},{"month":6,"riseRate":0.347826,"avgChangeRate":0.004417},{"month":7,"riseRate":0.652174,"avgChangeRate":0.052281},{"month":8,"riseRate":0.434783,"avgChangeRate":-0.006702},{"month":9,"riseRate":0.391304,"avgChangeRate":-0.014985},{"month":10,"riseRate":0.545455,"avgChangeRate":0.024642},{"month":11,"riseRate":0.5,"avgChangeRate":0.067433},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.011901}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SBP GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}